Universidad Peruana Cayetano Heredia

Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis

Mostrar el registro sencillo del ítem

dc.contributor.author Llanos Cuentas, Elmer Alejandro
dc.contributor.author Echevarria Zarate, Juan Ignacio
dc.contributor.author Cruz, M.
dc.contributor.author La Rosa, A.
dc.contributor.author Campos, P.
dc.contributor.author Campos, M.
dc.contributor.author Franke, E.
dc.contributor.author Berman, J.
dc.contributor.author Modabber, F.
dc.contributor.author Marr, J.
dc.date.accessioned 2022-10-09T22:16:53Z
dc.date.available 2022-10-09T22:16:53Z
dc.date.issued 1997
dc.identifier.uri https://hdl.handle.net/20.500.12866/12306
dc.description.abstract A randomized, open, controlled clinical trial was designed to evaluate the efficacy, tolerance, and safety of sodium stibogluconate plus allopurinol and sodium stibogluconate alone as treatment of patients with mucocutaneous leishmaniasis. In phase 1 of the study, all 22 patients with severe disease had improvement of their lesions, but only two had clinical cure (both of these patients received sodium stibogluconate alone). In phase 2, which included 59 patients with moderate disease, the cure rate among sodium stibogluconate recipients was 75% (21 of 28) compared with 63.6% (14 of 22) among the sodium stibogluconate plus allopurinol recipients. The rates of clinical adverse events were similar among both groups. Thrombocytopenia was more frequent in the sodium stibogluconate plus allopurinol recipients, but the difference was not statistically significant. Eight patients (two sodium stibogluconate recipients and six sodium stibogluconate plus allopurinol recipients) withdrew from the study because of severe thrombocytopenia. In this study, the addition of allopurinol to sodium stibogluconate provided no clinical benefit as treatment of mucocutaneous leishmaniasis. en_US
dc.language.iso eng
dc.publisher Oxford University Press
dc.relation.ispartofseries Clinical Infectious Diseases
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Meglumine Antimonate en_US
dc.subject Leishmania en_US
dc.subject Miltefosine en_US
dc.title Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1086/513776
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.03.08
dc.relation.issn 1537-6591


Ficheros en el ítem

Ficheros Tamaño Formato Ver

No hay ficheros asociados a este ítem.

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

info:eu-repo/semantics/restrictedAccess Excepto si se señala otra cosa, la licencia del ítem se describe como info:eu-repo/semantics/restrictedAccess

Buscar en el Repositorio


Listar

Panel de Control

Estadísticas